neuromodulators

ASDS Annual Survey Reveals Increase in Cosmetic and Skin Cancer Treatments

Cosmetic Procedures Up

There was a 7.5 percent increase in demand for cosmetic procedures in 2018, according to the results of the 2018 American Society for Dermatologic Surgery (ASDS) member survey, and a 60 percent increase since 2012. ASDS members performed 3.5 million skin cancer treatments and nearly nine million cosmetic treatments last year.

The top cosmetic treatments in 2018 were:

Bonti Releases Phase 2A Clinical Study Data for its Botulinum Toxin Product

New E serotype E botulinum toxin completes first clinical trial

Bonti, a clinical-stage biotechnology company, has announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours) and short duration of effect (about 4 weeks).

Modulating Expression

Physicians share their techniques for obtaining better longevity and more natural-looking results with botulinum toxins.
Improving longevity and outcomes with neurotoxins

What started as a simple injection to lessen crow’s feet has blossomed into a multibillion dollar market and given rise to today’s medical aesthetics industry. With nearly 30 years of experience and a growing variety of botulinum toxins entering the market, the current focus in neuromodulation is on extending the longevity of results and delivering natural-looking outcomes.